WHO Approves Trials for Two New Ebola Vaccines Amid DRC Outbreak

The World Health Organization has granted approval for clinical trials focusing on two novel Ebola vaccines, marking a critical step as medical professionals work to curb the most extensive outbreak in the history of the Democratic Republic of the Congo. During expert group meetings, health officials recommended integrating these new trials to combat the Bundibugyo virus, which has claimed more than 5,300 lives since May. Public health agencies have faced significant challenges in containing this specific strain due to a fifty percent fatality rate and the absence of targeted treatments or vaccines.

Tedros Adhanom Ghebreyesus, the WHO chief, noted that ongoing trials previously relied on the Ervebo vaccine, which was formulated for the Zaire strain rather than Bundibugyo. The newly approved vaccines have been developed through a collaboration involving the University of Oxford, the Serum Institute of India, and Moderna. Results from these latest evaluations are anticipated by early 2027. The National Institute for Biomedical Research in the DRC is spearheading the study with support from international partners.

WHO greenlights clinical trials for two novel vaccines targeting the lethal Bundibugyo Ebola strain.

While vaccine development progresses, the WHO stresses that immunization cannot replace foundational public health measures, including early medical care, isolation, contact tracing, and safe burial practices. African health authorities report that confirmed cases of the Bundibugyo virus have surpassed ten thousand, while limited cases have emerged in Kenya and Nigeria. Meanwhile, international travel restrictions have drawn criticism from health leaders who warn that such measures discourage transparency and hinder coordinated containment efforts across neighboring nations.

In a separate development, a British healthcare worker who contracted the virus in the DRC is being transferred to the United Kingdom for specialized medical care. Officials confirmed that the patient remains in a stable condition and will be admitted to a high-consequence infectious disease unit upon arrival, though the overall risk to the domestic public remains very low.

Why it matters

The introduction of targeted clinical trials represents a vital shift in managing the deadliest strain of the virus currently lacking a specific countermeasure. This development directly impacts global health strategies, international containment protocols, and medical research partnerships involving institutions like the Serum Institute of India.